NCT07388524 2026-03-17
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
National Cancer Institute (NCI)
Phase 3 Not yet recruiting
Clinical Trials
14 trialsNCT07457099 2026-03-09
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Zhujiang Hospital
Not yet recruiting
NCT07281547 2026-02-18
Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain
Mayo Clinic
Phase 4 Not yet recruiting
NCT07240220 2026-01-15
Merck-4
Indiana University
Phase NA Not yet recruiting
NCT07338968 2026-01-14
CoMpass
Aura Biosciences
Not yet recruiting
NCT06792994 2025-12-02
CLL2000
German CLL Study Group
Not yet recruiting
NCT07023432 2025-06-17
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT06998342 2025-05-31
MOHSAHRTSS
University of Vermont Medical Center
Phase 2 Not yet recruiting
NCT06861894 2025-05-15
Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT06974370 2025-05-15
ACTION-Brain
University of Vermont Medical Center
Phase 2 Not yet recruiting
NCT06686381 2025-02-05
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
American University of Beirut Medical Center
Phase 2 Not yet recruiting
NCT06653257 2024-10-29
Active Surveillance Program in Thyroid Nodules
Centro de Excelencia en Enfermedades de Cabeza y Cuello
Not yet recruiting
NCT06089369 2024-04-30
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Tongji Hospital
Phase 3 Not yet recruiting
NCT05661110 2022-12-22
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Not yet recruiting